Italian Study for Congenital Platelet Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-15

Study Completion Date

2028-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inherited platelet disorders (IPD) are a heterogeneous group of rare bleeding diseases associated with a reduction of platelet number and/or function and with a bleeding tendency ranging from mild to severe. The frequency of inherited thrombocytopenias has been estimated to be 2.7/100,000 while the prevalence of inherited platelet function disorders is unknown, partly because they are frequently overlooked due to their difficult diagnosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eltrombopag for Inherited Thrombocytopenias

NCT02422394

Inherited Platelet Disorder

COMPLETED PHASE2

Italian iTTP Registry

NCT06376786

TTP - Thrombotic Thrombocytopenic Purpura

RECRUITING

Risk Factors for Thrombosis in Immune Thrombocytopenia

NCT03820960

Immune Thrombocytopenia

COMPLETED

Investigation on a Dynamic Cohort of Italian Patients With Active ITP

NCT03465020

Idiopathic Thrombocytopenic Purpura

UNKNOWN

Association of TNFAIP3 With Immune-mediated TTP

NCT06928233

Thrombotic Thrombocytopenic Purpura, Acquired

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This a no-profit national multicenter ambispectic (retrospective and prospective) observational study.

After collection of informed consent form each patient, each center will enroll the patient and will collect general, laboratory and clinical data on an electronic CRF on a REDCAP platform. Each patient will receive a unique identification number. All clinical events will be reported in the data base.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients with established diagnosis will be enrolled.

All patients with established diagnosis of inherited number or function platelet disorder (IPN and IPD, respectively), on the basis of internationally established clinical, laboratory and genetic criteria will be enrolled.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with established diagnosis of inherited number or function platelet disorder (IPN and IPD, respectively), on the basis of internationally established clinical, laboratory and genetic criteria will be enrolled.
* For patients \<18 ys, consensus will be signed by parents or legal responsible